Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Dannae Brown"'
Autor:
Emmanuelle Papot, Simone Jacoby, Dona Arlinda, Anchalee Avihingsanon, Iskandar Azwa, Margaret Borok, Dannae Brown, Mohamed Cissé, Sounkalo Dao, Nnakelu Eriobu, Richard Kaplan, Muhammad Karyana, Nagalingeswaran Kumarasamy, Johnnie Lee, Marcelo H. Losso, Gail V. Matthews, Leonardo Perelis, Carmen Perez-Casas, Kiat Ruxrungtham, Melynda Watkins, H. Clifford Lane, Anthony Kelleher, Matthew Law, Mark N. Polizzotto
Publikováno v:
HIV Research & Clinical Practice, Vol 23, Iss 1, Pp 37-46 (2022)
A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled no
Externí odkaz:
https://doaj.org/article/1e534f2c23af4fa8b68b25301742d28b
Autor:
Elmira Mamedova, Maria Claudia Nascimento, Fujie Zhang, Marcelo H. Losso, Jörg Sievers, Richard Kaplan, Judy Hopking, Dannae Brown, Mark R. Underwood, Ploenchan Chetchotisakd, Johannes Lombaard, Kimberly Y. Smith, Yogesh Punekar, Michael Aboud, Martin Gartland, Carlos Brites, José A Hidalgo
Publikováno v:
The Lancet Infectious Diseases. 19:253-264
Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptas
Autor:
Dannae Brown, Richard Kaplan, Marcelo Losso, Carlos Brites, Ruolan Wang, Mark Underwood, Judy Hopking, Michael Aboud, Jörg Sievers
Publikováno v:
Antiviral Therapy. 27:135965352210774
Background In the DAWNING study, dolutegravir + 2 nucleoside reverse transcriptase inhibitors (NRTIs) demonstrated superior efficacy at Week 48 and a favourable safety profile compared with lopinavir/ritonavir + 2 NRTIs in adults with HIV-1 failing f
Autor:
Jean van Wyk, Michael Aboud, Dannae Brown, Marty St. Clair, Leigh Ragone, Cassidy Henegar, James F. Demarest, José M. Gatell, Vani Vannappagari, Annemiek de Ruiter, Mark R. Underwood, Romina Quercia
Publikováno v:
Antiviral therapy. 24(6)
Background Pretreatment and acquired drug resistance mutations (DRMs) can limit antiretroviral therapy effectiveness. Methods We review prevalence of DRMs with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside rever
Autor:
Kelly E, Dooley, Richard, Kaplan, Noluthando, Mwelase, Beatriz, Grinsztejn, Eduardo, Ticona, Marcus, Lacerda, Omar, Sued, Elena, Belonosova, Mounir, Ait-Khaled, Konstantinos, Angelis, Dannae, Brown, Rajendra, Singh, Christine L, Talarico, Allan R, Tenorio, Michael R, Keegan, Michael, Aboud, Avihingsanon, Anchalee
Publikováno v:
Clinical Infectious Diseases.
The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG)
Autor:
Marty St. Clair, Andrew Zolopa, Mark R. Underwood, Dannae Brown, David Dorey, James F. Demarest
Publikováno v:
AIDS Research and Human Retroviruses
In the SAILING study, dolutegravir demonstrated superior virologic efficacy compared with raltegravir in treatment-experienced, integrase strand transfer inhibitor (INSTI)–naive patients with HIV-1 who harbored resistance to ≥2 antiretroviral dru
Autor:
Kelly Dooley, Richard Kaplan, Noluthando Mwelase, Beatriz Grinsztejn, Eduardo Ticona, Marcus Lacerda, Omar Sued, Elena Belonosova, Mounir Ait-Khaled, Konstantinos Angelis, Dannae Brown, Rajendra Singh, Christine L. Talarico, Allan Tenorio, Michael R. Keegan, Michael Aboud, INSPIRING Study Group
Publikováno v:
SSRN Electronic Journal.
Background: Concurrent treatment of tuberculosis and HIV is challenging owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir were assessed in adults with H
Autor:
Mounir Ait-Khaled, Marcus V. G. Lacerda, Richard Kaplan, Michael Aboud, Christine L. Talarico, Eduardo Ticona, Kelly E. Dooley, Kostas Angelis, Allan R. Tenorio, Roberto Zajdenverg, Omar Sued, Beatriz Grinsztejn, Elena Belonosova, Rajendra P. Singh, Noluthando Mwelase, Michael Keegan, Dannae Brown
Publikováno v:
The Brazilian Journal of Infectious Diseases. 22:14-15
Autor:
Rimgaile Urbaityte, Dannae Brown, Pedro E Ferrer, David Baker, David Orth, Mark Bloch, Norman Roth, Ken Koh, Fraser Drummond, Robert Finlayson
Publikováno v:
International Journal of STD & AIDS
The most common reasons for switching HIV-1 therapy in patients with virologic suppression are treatment regimen simplification and resolving tolerability issues. Single-pill regimens that include an integrase inhibitor are recommended options. A ret
Autor:
Dannae Brown, Johannes Lombaard, Elmira Mamedova, Judy Hopking, Fujie Zhang, Maria Claudia Nascimento, Jörg Sievers, Richard Kaplan, Ploenchan Chetchotisakd, Kimberly Y. Smith, Martin Gartland, Marcelo H. Losso, Michael Aboud, José A Hidalgo, Carlos Brites, Rita Manzano Sarti, Mark R. Underwood
Publikováno v:
The Brazilian Journal of Infectious Diseases. 22:56